Combination of Venetoclax and Cudc-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo
Xinyu Li,Jun Ma,Yongwei Su,Jianyun Zhao,Holly Edwards,Yue Wang,Jay Yang,Jeffrey W. Taub,Hai Lin,Yubin Ge
DOI: https://doi.org/10.1182/blood.v128.22.1571.1571
IF: 20.3
2016-01-01
Blood
Abstract:Overall survival rates for adults and children with acute myeloid leukemia (AML) remain unacceptably low. Resistance to chemotherapy is the major factor contributing to such dismal overall survival rates. Chemoresistance in leukemia cell line models has been associated with overexpression of the anti-apoptotic Bcl-2 family members. As such, small molecule Bcl-2 inhibitors represent a promising strategy for treating AML.
What problem does this paper attempt to address?